Back to Search
LOUISE GROCHOW, M.D.
M.D.
Medical Oncology Physician
NPI: 1326159674Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D0018333(MD)
Research & Publications (20)
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
PMID 16849749·J Clin Oncol·2006
3-trial
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.
PMID 15774780·J Clin Oncol·2005
3-trial
Risks and benefits of phase 1 oncology trials, 1991 through 2002.
PMID 15745980·N Engl J Med·2005
8-other
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
PMID 12488482·J Natl Cancer Inst·2002
8-other
Parenteral busulfan: is therapeutic monitoring still warranted?
PMID 12374450·Biol Blood Marrow Transplant·2002
8-other
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
PMID 11948101·Clin Cancer Res·2002
3-trial
Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans.
PMID 11820510·Xenobiotica·2002
8-other
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors.
PMID 11710626·Cancer Chemother Pharmacol·2001
3-trial
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
PMID 11595694·Clin Cancer Res·2001
3-trial
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
PMID 11489809·Clin Cancer Res·2001
3-trial
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
PMID 11489804·Clin Cancer Res·2001
3-trial
Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas.
PMID 11432894·J Clin Oncol·2001
3-trial
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
PMID 11304769·J Clin Oncol·2001
3-trial
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
PMID 11134207·J Clin Oncol·2001
3-trial
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
PMID 11072167·Int J Radiat Oncol Biol Phys·2000
8-other
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
PMID 11051234·Clin Cancer Res·2000
3-trial
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.
PMID 10923100·Cancer Invest·2000
8-other
Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study.
PMID 10905771·Biol Blood Marrow Transplant·2000
8-other
Population pharmacokinetic model for topotecan derived from phase I clinical trials.
PMID 10856106·J Clin Oncol·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- JOHNS HOPKINS HOSP ONCOLOGY CTG C/O MARTIN ABELOFF, 600 N. WOLFE ST.
BALTIMORE, MD 21287 - Phone
- (302) 252-5044
Quick Facts
- NPI
- 1326159674
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile